Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial

Published:2024-04-30 Issue: Volume: Page:
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Shin Junghoon,Park Sehhoon,Kim Kyung Hwan,Shin Eui-Cheol,Jung Hyun Ae,Cho Jong Ho,Sun Jong-Mu,Lee Se-Hoon,Choi Yong Soo,Ahn Jin Seok,Kim Jhingook,Park Keunchil,Shim Young Mog,Kim Hong Kwan,Noh Jae Myoung,Ahn Yong Chan,Pyo Hongryull,Ahn Myung-Ju

Publisher

Korean Cancer Association

Link

http://e-crt.org/upload/pdf/crt-2024-084.pdf

Reference31 articles.

1. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

2. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

3. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP